Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which ...
Nasdaq

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has ...
Yahoo Finance

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Seeking Alpha

Alpha Tau Medical: 2026 Is The Breakthrough Year

Alpha Tau Medical pioneers localized alpha particle radiation for solid tumors, with its Alpha DaRT technology showing broad applicability and strong early efficacy. 2026 is pivotal for DRTS, with ...

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

First glioblastoma patient ever treated with Alpha DaRT® outside of the United States, and the first in Israel - performed at Hadassah ...
Physics World

Alpha DaRT treatment proves a success in first-in-human trial

Alpha DaRT technology uses diffusing alpha emitters to treat solid tumours. (Courtesy: Alpha Tau Medical) Diffusing alpha-emitters radiation therapy (DaRT) uses interstitial radioactive seeds that ...